Page 109 - 2020年20期

pay for insulin delivery systems in type 1 and type 2 diabe- preferences for diabetes treatment attributes and drug
tes[J]. Diabetes Technol Ther，2009，11（9）：567-573. classes[J]. Curr Med Res Opin，2017，33（2）：261-268.
[30] MORILLAS C，FELICIANO R，CATALINA PF，et al. Pa- [41] JANSSEN EM，LONGO DR，BARDSLEY JK，et al. Edu-
tients’and physicians’preferences for type 2 diabetes cation and patient preferences for treating type 2 diabetes：
mellitus treatments in Spain and Portugal：a discrete a stratified discrete-choice experiment[J]. Patient Prefer
choice experiment[J]. Patient Prefer Adher，2015. DOI： Adher，2017. DOI：10.2147/PPA.S139471.
10.2147/PPA.S88022. [42] HERTROIJS DFL，ELISSEN AMJ，BROUWERS MCGJ，
[31] BROOKS A，LANGER J，TERVONEN T，et al. Patient et al. Preferences of people with type 2 diabetes for diabe-
preferences for GLP-1 receptor agonist treatment of type tes care：a discrete choice experiment[J]. Diabet Med，
2 diabetes mellitus in Japan：a discrete choice experi- 2019. DOI：10.1111/dme.13969.
ment[J]. Diabetes Ther，2019，10（2）：735-749. [43] DONNAN JR，JOHNSTON K，CHIBRIKOV E，et al.
[32] MANSFIELD C，SIKIRICA MV，PUGH A，et al. Patient Capturing adult patient preferences toward benefits and
preferences for attributes of type 2 diabetes mellitus medi- risks of second-line antihyperglycemic medications used
cations in germany and spain：an online discrete-choice ex- in type 2 diabetes：a discrete choice experiment[J]. Can J
periment survey[J]. Diabetes Ther，2017，8（6）：1365- Diabetes，2020，44（1）：6-13.
1378. [44] MANGHAM LJ，HANSON K，MCPAKE B. How to do
[33] ARISTIDES M，WESTON AR，FITZGERALD P，et al. （or not to do）：designing a discrete choice experiment for
Patient preference and willingness-to-pay for humalog application in a low-income country[J]. Health Policy
mix25 relative to humulin 30/70：a multicountry applica- Plann，2009，24（2）：151-158.
tion of a discrete choice experiment[J]. Value Health， [45] SOEKHAI V，DE BEKKER-GROB EW，ELLIS AR. Dis-
2004，7（4）：442-454. crete choice experiments in health economics：past，pre-
[34] HAUBER AB，HAN S，YANG JC，et al. Effect of pill bur- sent and future[J]. Pharmacoeconomics，2018，37（2）：
den on dosing preferences，willingness to pay，and likely 201-226.
adherence among patients with type 2 diabetes[J]. Patient [46] ORME BK. Getting started with conjoint analysis：strate-
Prefer Adher，2013. DOI：10.2147/PPA.S43465. gies for product design and pricing research[M]. 3rd edi-
[35] GELHORN HL，POON JL，DAVIES EW，et al. Evaluat- tion. Madison：Research Publishers LLC，2014：1-234.
ing preferences for profiles of GLP-1 receptor agonists [47] DAVIS S，ALONSO MD. Hypoglycemia as a barrier to
among injection-naive type 2 diabetes patients in the glycemic control[J]. J Diabetes Complications，2004，18
UK[J]. Patient Prefer Adher，2015. DOI：10.2147/PPA. （1）：60-68.
S90842. [48] 胡善联.算好社会意愿支付价这道题[N].医药经济报，
[36] GELHORN HL，BACCI ED，POON JL，et al. Evaluating 2020-05-07（封3）.
preferences for profiles of glucagon-like peptide-1 recep- [49] 陈娟.国产与合资二甲双胍片治疗2型糖尿病的成本-效
tor agonists among injection-naive type 2 diabetes pa- 果分析[J].中国药房，2007，18（20）：1529-1530.
tients in Japan[J]. Patient Prefer Adher，2016. DOI： [50] EICHLER HG，ABADIE E，BRECKENRIDGE A，et al.
10.2147/PPA.S109289. Bridging the efficacy-effectiveness gap：aregulator’s per-
[37] BOGELUND M，VILSBOLL T，FABER J，et al. Patient spective on addressing variability of drug response[J]. Nat
preferences for diabetes management among people with Rev Drug Discov，2011，10（7）：495-506.
type 2 diabetes in Denmark：a discrete choice experi- [51] VON ARX LB，KJEER T. The patient perspective of dia-
ment[J]. Curr Med Res Opin，2011，27（11）：2175-2183. betes care：a systematic review of stated preference re-
[38] GELHORN HL，STRINGER SM，BROOKS A，et al. Pref- search[J]. Patient，2014，7（3）：283-300.
erences for medication attributes among patients with type [52] MAGAI C，CONSEDINE N，NEUGUT AI，et al. Com-
2 diabetes mellitus in the UK[J]. Diabetes Obes Metab， mon psychosocial factors underlying breast cancer screen-
2013，15（9）：802-809. ing and breast cancer treatment adherence：a conceptual re-
[39] FEHER MD，BRAZIER J，SCHAPER N，et al. Patients’ view and synthesis[J]. J Womens Health：Larchmt，2007，
with type 2 diabetes willingness to pay for insulin therapy 16（1）：11-23.
and clinical outcomes[J]. BMJ Open Diabetes Res Care， （收稿日期：2020-05-06 修回日期：2020-09-07）
2016. DOI：10.1136/bmjdrc-2016-000192. （编辑：孙 冰）
[40] FLOOD EM，BELL KF，DE LA CRUZ MC，et al. Patient

中国药房 2020年第31卷第20期 China Pharmacy 2020 Vol. 31 No. 20 ·2531 ·